Market Overview - The stock market experienced a strong finish in 2024, driven by optimism around potential tax cuts and a robust M&A environment, but sentiment shifted in early 2025 due to concerns over tariffs, AI spending, and consumer health [2][3] - A remarkable recovery occurred in the second quarter of 2025, with U.S. equities approaching all-time highs, primarily led by large-cap technology and growth stocks, especially those related to AI and semiconductors [3] Fund Performance - Ariel Focus Fund gained +4.75% for the three-month period ending June 30, 2025, outperforming its primary Russell 1000 Value Index, which rose +3.79%, but lagged behind the S&P 500, which jumped +10.94% [4] - Key contributors to the fund's performance included Oracle Corporation, Mosaic Company, and Resideo Technologies, while J.M. Smucker Company, APA Corporation, and Core Laboratories were the largest detractors [4][10][12] Company Insights - Oracle Corporation's shares reached an all-time high of over $245, driven by a potential $30 billion annual cloud contract with OpenAI and a doubling of its backlog, highlighting its strong long-term positioning in AI-driven enterprise software [6] - Mosaic Corporation's stock rose +35.88% due to favorable trade dynamics and a renewed focus on cost discipline, benefiting from increased demand for fertilizers driven by economic growth in developing countries [7][8] - Resideo Technologies rebounded with a +24.63% gain, supported by its leadership in smart home technology, despite challenges from a sluggish U.S. housing market [9] Challenges Faced - J.M. Smucker Company faced a -16.28% decline, primarily due to disappointing results from Hostess Brands, which saw a -14% drop in comparable revenue [10] - APA Corporation and Core Laboratories experienced declines of -11.62% and -23.09%, respectively, amid concerns about the energy sector's future despite ongoing demand for oil and gas [12][13]

Core Insights - Core Laboratories Inc. (CLB) reported third-quarter 2025 adjusted earnings of 22 cents per share, exceeding the Zacks Consensus Estimate of 19 cents, primarily due to the strong performance of the Production Enhancement segment, although it declined from 27 cents in the previous year due to underperformance in the Reservoir Description segment [1][10]. Financial Performance - The company achieved third-quarter operating revenues of $134.5 million, surpassing the Zacks Consensus Estimate of $128 million, driven by increased demand for laboratory analytical and completion diagnostic services in international markets, with revenues remaining flat year over year [2][10]. - Total costs and expenses for the third quarter were reported at $113.6 million, a decrease of 0.9% from $114.6 million in the previous year, aligning closely with the estimate of $113.5 million [7]. - As of September 30, 2025, CLB had cash and cash equivalents of $25.6 million and long-term debt of $114.1 million, with a debt-to-capitalization ratio of 29.1% [8]. Segment Performance - In the Reservoir Description segment, revenues decreased by 0.7% year over year to $88.2 million, although it exceeded the estimate of $84 million, driven by increased demand for rock and fluid analysis [4]. - The Production Enhancement segment saw revenues increase by 1.6% to $46.3 million, surpassing the estimate of $43.5 million, with operating income rising from $2.6 million to $4.9 million, also beating the estimate of $3.3 million [5][6]. Shareholder Returns - The company repurchased 462,248 shares of common stock for a total of $5 million during the third quarter [3]. - The board of directors approved a quarterly dividend of 1 cent per share, unchanged from the previous quarter, to be paid on November 24, 2025 [9]. Future Outlook - For the fourth quarter of 2025, CLB expects revenues to range from $132 million to $136 million, with operating income anticipated between $14 million and $16.1 million, and earnings per share projected between 18 cents and 22 cents [12]. - The company maintains a positive long-term outlook, driven by consistent activity in long-cycle developments, particularly in deepwater regions [11]. Industry Context - Global crude oil demand is projected to rise by 0.7-1.3 million barrels per day in 2025, with similar growth expected in 2026, particularly in non-OECD markets [14]. - The IEA highlights the need for sustained investment in new developments to address long-term supply risks due to declining rates in existing oil fields, positioning Core Laboratories' services favorably to support these investment needs [14].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ______________ Commission File Number: 001-41695 CORE LABORATORIES INC. (Exact name of registrant as specified in its charter) Delawar ...

Core Laboratories (NYSE:CLB) Q3 2025 Earnings Call October 23, 2025 08:30 AM ET Company ParticipantsChris Hill - CFOJohn Daniel - Founder and Managing PartnerLarry Bruno - Chairman and CEOGwen Gresham - SVP and Head of Investor RelationsOperatorToday, and welcome to the Core Laboratories Q3 2025 earnings call. All participants will be in the listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be ...

Core Laboratories (NYSE:CLB) Q3 2025 Earnings Call October 23, 2025 08:30 AM ET Company ParticipantsChris Hill - CFOJohn Daniel - Founder and Managing PartnerLarry Bruno - Chairman and CEOGwen Gresham - SVP and Head of Investor RelationsOperatorToday, and welcome to the Core Laboratories Inc. Q3 2025 earnings call. All participants will be in the listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there wi ...

Core Laboratories (NYSE:CLB) Q3 2025 Earnings Call October 23, 2025 08:30 AM ET Speaker2Today, and welcome to the Core Laboratories Inc. Q3 2025 earnings call. All participants will be in the listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone phone. To withdraw your question, please press star the ...

Core Laboratories (NYSE:CLB) Q3 2025 Earnings Call October 23, 2025 08:30 AM ET Speaker0Good day, and welcome to the Core Laboratories Q3 twenty twenty five Earnings Call. All participants will be in a listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Larry Bruno, Chairman and CEO. Please go ahead.Speaker1Thanks, Danielle. Good morning in The Americas, good afternoon in Europe, Africa and The Middle East and good evening in Asia Pacific. We'd like to ...

Core Earnings Performance - Core Laboratories reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.19 per share, but down from $0.25 per share a year ago, representing an earnings surprise of +15.79% [1] - The company posted revenues of $134.52 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.50%, and showing a slight increase from year-ago revenues of $134.4 million [2] Stock Performance and Outlook - Core Laboratories shares have declined approximately 30.5% since the beginning of the year, contrasting with the S&P 500's gain of 14.5% [3] - The company's current consensus EPS estimate for the upcoming quarter is $0.20 on revenues of $126.9 million, and for the current fiscal year, it is $0.72 on revenues of $508.15 million [7] Industry Context - The Oil and Gas - Field Services industry, to which Core Laboratories belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

• REVENUE OF $134.5 MILLION, UP OVER 3% SEQUENTIALLY AND FLAT YEAR-OVER-YEAR FOR IMMEDIATE RELEASE CORE LAB REPORTS THIRD QUARTER 2025 RESULTS: Exhibit 99.1 HOUSTON (October 22, 2025) - Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2025 revenue of $134,500,000. Core's operating income was $20,900,000, with earnings per diluted share ("EPS") of $0.30, all in accordance with U.S. generally accepted accounting principles ("GAAP"). Operating income, ex-items, ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...